伦理学 发表于 2025-3-30 09:00:40

The Role of Interferon for the Treatment of Chronic Hepatitis C Virus InfectionN-α). While this reduced the need for subcutaneous injections from three times a week to once a week which improved patients’ adherence, the increase in SVR with PegIFN-α over standard IFN-α was relatively modest. Further, drug-related side effects remained problematic, limiting HCV treatment uptake

conceal 发表于 2025-3-30 16:17:53

http://reply.papertrans.cn/43/4202/420175/420175_52.png

magenta 发表于 2025-3-30 17:35:59

Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerasemplex inhibitor daclatasvir and the NS3 protease inhibitor asunaprevir in a single, fixed-dose formulation (Ximency) resulted in the approval by the Japanese Pharmaceutical and Food Safety Bureau for its use in the treatment of patients infected with genotype 1 HCV.

臆断 发表于 2025-3-31 00:12:22

http://reply.papertrans.cn/43/4202/420175/420175_54.png

Lumbar-Spine 发表于 2025-3-31 04:04:14

http://reply.papertrans.cn/43/4202/420175/420175_55.png

TIA742 发表于 2025-3-31 08:04:19

Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1e compound libraries did not result in any starting point for SAR optimization. Introduction of electrophilic traps to natural substrate of the enzyme identified a ketoamide-derived undecapeptide lead. It was optimized to identify the first ketoamide-derived direct-acting antiviral agent for the tre

子女 发表于 2025-3-31 09:47:21

http://reply.papertrans.cn/43/4202/420175/420175_57.png
页: 1 2 3 4 5 [6]
查看完整版本: Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir